Literature DB >> 29288199

Comparison of T Cell Activities Mediated by Human TCRs and CARs That Use the Same Recognition Domains.

Daniel T Harris1, Marlies V Hager1, Sheena N Smith1, Qi Cai1, Jennifer D Stone1, Philipp Kruger2, Melissa Lever2, Omer Dushek2, Thomas M Schmitt3, Philip D Greenberg3,4, David M Kranz5.   

Abstract

Adoptive T cell therapies have achieved significant clinical responses, especially in hematopoietic cancers. Two types of receptor systems have been used to redirect the activity of T cells, normal heterodimeric TCRs or synthetic chimeric Ag receptors (CARs). TCRs recognize peptide-HLA complexes whereas CARs typically use an Ab-derived single-chain fragments variable that recognizes cancer-associated cell-surface Ags. Although both receptors mediate diverse effector functions, a quantitative comparison of the sensitivity and signaling capacity of TCRs and CARs has been limited due to their differences in affinities and ligands. In this study we describe their direct comparison by using TCRs that could be formatted either as conventional αβ heterodimers, or as single-chain fragments variable constructs linked to CD3ζ and CD28 signaling domains or to CD3ζ alone. Two high-affinity TCRs (KD values of ∼50 and 250 nM) against MART1/HLA-A2 or WT1/HLA-A2 were used, allowing MART1 or WT1 peptide titrations to easily assess the impact of Ag density. Although CARs were expressed at higher surface levels than TCRs, they were 10-100-fold less sensitive, even in the absence of the CD8 coreceptor. Mathematical modeling demonstrated that lower CAR sensitivity could be attributed to less efficient signaling kinetics. Furthermore, reduced cytokine secretion observed at high Ag density for both TCRs and CARs suggested a role for negative regulators in both systems. Interestingly, at high Ag density, CARs also mediated greater maximal release of some cytokines, such as IL-2 and IL-6. These results have implications for the next-generation design of receptors used in adoptive T cell therapies.
Copyright © 2018 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29288199      PMCID: PMC5780198          DOI: 10.4049/jimmunol.1700236

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  59 in total

1.  TCRs with high affinity for foreign pMHC show self-reactivity.

Authors:  Phillip D Holler; Lukasz K Chlewicki; David M Kranz
Journal:  Nat Immunol       Date:  2002-12-09       Impact factor: 25.606

2.  Cancer regression in patients after transfer of genetically engineered lymphocytes.

Authors:  Richard A Morgan; Mark E Dudley; John R Wunderlich; Marybeth S Hughes; James C Yang; Richard M Sherry; Richard E Royal; Suzanne L Topalian; Udai S Kammula; Nicholas P Restifo; Zhili Zheng; Azam Nahvi; Christiaan R de Vries; Linda J Rogers-Freezer; Sharon A Mavroukakis; Steven A Rosenberg
Journal:  Science       Date:  2006-08-31       Impact factor: 47.728

3.  Therapeutic efficacy of an Fc-enhanced TCR-like antibody to the intracellular WT1 oncoprotein.

Authors:  Nicholas Veomett; Tao Dao; Hong Liu; Jingyi Xiang; Dmitry Pankov; Leonid Dubrovsky; Joseph A Whitten; Sun-Mi Park; Tatyana Korontsvit; Victoria Zakhaleva; Emily Casey; Michael Curcio; Michael G Kharas; Richard J O'Reilly; Cheng Liu; David A Scheinberg
Journal:  Clin Cancer Res       Date:  2014-05-21       Impact factor: 12.531

4.  Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia.

Authors:  Julie C Fitzgerald; Scott L Weiss; Shannon L Maude; David M Barrett; Simon F Lacey; J Joseph Melenhorst; Pamela Shaw; Robert A Berg; Carl H June; David L Porter; Noelle V Frey; Stephan A Grupp; David T Teachey
Journal:  Crit Care Med       Date:  2017-02       Impact factor: 7.598

5.  Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells.

Authors:  Cameron J Turtle; Laïla-Aïcha Hanafi; Carolina Berger; Michael Hudecek; Barbara Pender; Emily Robinson; Reed Hawkins; Colette Chaney; Sindhu Cherian; Xueyan Chen; Lorinda Soma; Brent Wood; Daniel Li; Shelly Heimfeld; Stanley R Riddell; David G Maloney
Journal:  Sci Transl Med       Date:  2016-09-07       Impact factor: 17.956

6.  Therapeutic bispecific T-cell engager antibody targeting the intracellular oncoprotein WT1.

Authors:  Tao Dao; Dmitry Pankov; Andrew Scott; Tatyana Korontsvit; Victoriya Zakhaleva; Yiyang Xu; Jingyi Xiang; Su Yan; Manuel Direito de Morais Guerreiro; Nicholas Veomett; Leonid Dubrovsky; Michael Curcio; Ekaterina Doubrovina; Vladimir Ponomarev; Cheng Liu; Richard J O'Reilly; David A Scheinberg
Journal:  Nat Biotechnol       Date:  2015-09-21       Impact factor: 54.908

7.  Targeting the intracellular WT1 oncogene product with a therapeutic human antibody.

Authors:  Tao Dao; Su Yan; Nicholas Veomett; Dmitry Pankov; Liang Zhou; Tatyana Korontsvit; Andrew Scott; Joseph Whitten; Peter Maslak; Emily Casey; Taochao Tan; Hong Liu; Victoria Zakhaleva; Michael Curcio; Ekaterina Doubrovina; Richard J O'Reilly; Cheng Liu; David A Scheinberg
Journal:  Sci Transl Med       Date:  2013-03-13       Impact factor: 17.956

Review 8.  Adoptive T Cell Therapies: A Comparison of T Cell Receptors and Chimeric Antigen Receptors.

Authors:  Daniel T Harris; David M Kranz
Journal:  Trends Pharmacol Sci       Date:  2015-12-17       Impact factor: 14.819

Review 9.  Phenotypic models of T cell activation.

Authors:  Melissa Lever; Philip K Maini; P Anton van der Merwe; Omer Dushek
Journal:  Nat Rev Immunol       Date:  2014-09       Impact factor: 53.106

10.  Biophysical mechanism of T-cell receptor triggering in a reconstituted system.

Authors:  John R James; Ronald D Vale
Journal:  Nature       Date:  2012-07-05       Impact factor: 49.962

View more
  46 in total

Review 1.  T-Cell Receptor-Based Immunotherapy for Hematologic Malignancies.

Authors:  Melinda A Biernacki; Michelle Brault; Marie Bleakley
Journal:  Cancer J       Date:  2019 May/Jun       Impact factor: 3.360

Review 2.  Navigating CAR-T cells through the solid-tumour microenvironment.

Authors:  Andrew J Hou; Laurence C Chen; Yvonne Y Chen
Journal:  Nat Rev Drug Discov       Date:  2021-05-10       Impact factor: 84.694

Review 3.  Applications of molecular engineering in T-cell-based immunotherapies.

Authors:  David A McBride; Matthew D Kerr; Shinya L Wai; Nisarg J Shah
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2019-04-10

4.  An Engineered T Cell Receptor Variant Realizes the Limits of Functional Binding Modes.

Authors:  Nishant K Singh; Jesus A Alonso; Daniel T Harris; Scott D Anderson; Jiaqi Ma; Lance M Hellman; Aaron M Rosenberg; Elizabeth M Kolawole; Brian D Evavold; David M Kranz; Brian M Baker
Journal:  Biochemistry       Date:  2020-10-19       Impact factor: 3.162

5.  High-Throughput Stability Screening of Neoantigen/HLA Complexes Improves Immunogenicity Predictions.

Authors:  Dylan T Blaha; Scott D Anderson; Daniel M Yoakum; Marlies V Hager; Yuanyuan Zha; Thomas F Gajewski; David M Kranz
Journal:  Cancer Immunol Res       Date:  2018-11-13       Impact factor: 11.151

Review 6.  Signaling from T cell receptors (TCRs) and chimeric antigen receptors (CARs) on T cells.

Authors:  Ling Wu; Qianru Wei; Joanna Brzostek; Nicholas R J Gascoigne
Journal:  Cell Mol Immunol       Date:  2020-05-25       Impact factor: 11.530

Review 7.  A Systematic Review of the Efforts and Hindrances of Modeling and Simulation of CAR T-cell Therapy.

Authors:  Ujwani Nukala; Marisabel Rodriguez Messan; Osman N Yogurtcu; Xiaofei Wang; Hong Yang
Journal:  AAPS J       Date:  2021-04-09       Impact factor: 4.009

8.  T-cell Receptors Engineered De Novo for Peptide Specificity Can Mediate Optimal T-cell Activity without Self Cross-Reactivity.

Authors:  Preeti Sharma; Daniel T Harris; Jennifer D Stone; David M Kranz
Journal:  Cancer Immunol Res       Date:  2019-09-23       Impact factor: 11.151

9.  Tuning the Antigen Density Requirement for CAR T-cell Activity.

Authors:  Robbie G Majzner; Skyler P Rietberg; Elena Sotillo; Rui Dong; Vipul T Vachharajani; Louai Labanieh; June H Myklebust; Meena Kadapakkam; Evan W Weber; Aidan M Tousley; Rebecca M Richards; Sabine Heitzeneder; Sang M Nguyen; Volker Wiebking; Johanna Theruvath; Rachel C Lynn; Peng Xu; Alexander R Dunn; Ronald D Vale; Crystal L Mackall
Journal:  Cancer Discov       Date:  2020-03-19       Impact factor: 39.397

10.  Structure-guided engineering of the affinity and specificity of CARs against Tn-glycopeptides.

Authors:  Preeti Sharma; Venkata V V R Marada; Qi Cai; Monika Kizerwetter; Yanran He; Steven P Wolf; Karin Schreiber; Henrik Clausen; Hans Schreiber; David M Kranz
Journal:  Proc Natl Acad Sci U S A       Date:  2020-06-15       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.